JP2023538945A5 - - Google Patents

Info

Publication number
JP2023538945A5
JP2023538945A5 JP2023513532A JP2023513532A JP2023538945A5 JP 2023538945 A5 JP2023538945 A5 JP 2023538945A5 JP 2023513532 A JP2023513532 A JP 2023513532A JP 2023513532 A JP2023513532 A JP 2023513532A JP 2023538945 A5 JP2023538945 A5 JP 2023538945A5
Authority
JP
Japan
Prior art keywords
sequence
cdr
polypeptide chain
antigen
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023513532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538945A (ja
JP7781859B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/114088 external-priority patent/WO2022042488A1/en
Publication of JP2023538945A publication Critical patent/JP2023538945A/ja
Publication of JP2023538945A5 publication Critical patent/JP2023538945A5/ja
Application granted granted Critical
Publication of JP7781859B2 publication Critical patent/JP7781859B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023513532A 2020-08-24 2021-08-23 抗ror1抗体及び関連の二重特異性結合タンパク質 Active JP7781859B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/110841 2020-08-24
CN2020110841 2020-08-24
CNPCT/CN2020/141398 2020-12-30
CN2020141398 2020-12-30
PCT/CN2021/114088 WO2022042488A1 (en) 2020-08-24 2021-08-23 Anti-ror1 antibodies and related bispecific binding proteins

Publications (3)

Publication Number Publication Date
JP2023538945A JP2023538945A (ja) 2023-09-12
JP2023538945A5 true JP2023538945A5 (cg-RX-API-DMAC7.html) 2024-08-28
JP7781859B2 JP7781859B2 (ja) 2025-12-08

Family

ID=77946069

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513532A Active JP7781859B2 (ja) 2020-08-24 2021-08-23 抗ror1抗体及び関連の二重特異性結合タンパク質

Country Status (12)

Country Link
US (1) US20240010753A1 (cg-RX-API-DMAC7.html)
EP (1) EP4200336A4 (cg-RX-API-DMAC7.html)
JP (1) JP7781859B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230053602A (cg-RX-API-DMAC7.html)
CN (2) CN114085288A (cg-RX-API-DMAC7.html)
AU (1) AU2021334677A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023002895A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190117A1 (cg-RX-API-DMAC7.html)
IL (1) IL300760A (cg-RX-API-DMAC7.html)
MX (1) MX2023002181A (cg-RX-API-DMAC7.html)
TW (1) TWI907489B (cg-RX-API-DMAC7.html)
WO (1) WO2022042488A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014374055B2 (en) * 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
CA3032430A1 (en) * 2016-08-16 2018-02-22 Epimab Biotherapeutics, Inc. Monovalent asymmetric tandem fab bispecific antibodies
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
CN114539411B (zh) * 2022-04-29 2022-11-11 山东博安生物技术股份有限公司 一种ror1抗体或其抗原结合片段
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ror1結合タンパク質を発現する細胞を培養する方法
CN118974090A (zh) * 2022-04-02 2024-11-15 山东先声生物制药有限公司 抗ror1的抗体及其用途
CA3262028A1 (en) * 2022-07-15 2025-06-13 Abl Bio Inc. Anti-ROR1 antibodies, bispecific antibodies containing it, and their uses
CN116836286A (zh) * 2022-09-07 2023-10-03 中国科学院合肥物质科学研究院 能够特异性结合ror1的抗体、其偶联药物及其制备方法和应用
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024094151A1 (en) * 2022-11-03 2024-05-10 Hansoh Bio Llc Multi-specific antibody and medical use thereof
AU2024331841A1 (en) * 2023-08-31 2026-03-05 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibody targeting receptor tyrosine kinase-like orphan receptor 1 and use thereof
WO2025061032A1 (zh) * 2023-09-18 2025-03-27 南京蓬勃生物科技有限公司 靶向人源ror1和cd3的双特异性抗体
TW202542204A (zh) * 2023-12-29 2025-11-01 大陸商上海岸邁生物科技有限公司 融合蛋白及其用途
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
CN122376773A (zh) * 2025-01-14 2026-07-14 正大天晴药业集团股份有限公司 靶向受体酪氨酸激酶样孤儿受体1的抗体药物偶联物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9242014B2 (en) * 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
EP3252076B1 (en) * 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
AU2014374055B2 (en) * 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
JP2017536341A (ja) * 2014-10-09 2017-12-07 エンクマフ アーゲー 卵巣がんの処置における使用のためのCD3εおよびROR1に対する二特異性抗体
EP3204415B1 (en) * 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
WO2016094873A2 (en) * 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
HK1253507A1 (zh) * 2015-05-18 2019-06-21 Eureka Therapeutics, Inc. 抗 ror1 抗体
HK1251480A1 (zh) * 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
CA3001941A1 (en) * 2015-10-30 2017-05-04 Nbe-Therapeutics Ag Anti-ror1 antibodies
CA3011419A1 (en) * 2016-01-22 2017-07-27 Janssen Biotech, Inc. Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same
AR108034A1 (es) * 2016-02-17 2018-07-11 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
CA3032430A1 (en) * 2016-08-16 2018-02-22 Epimab Biotherapeutics, Inc. Monovalent asymmetric tandem fab bispecific antibodies
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710838D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
KR102999339B1 (ko) * 2018-04-18 2026-07-31 엑셀리시스, 인코포레이티드 항-ror 항체 구조체
EA202192103A1 (ru) * 2019-01-29 2021-12-15 Джуно Терапьютикс, Инк. Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
CN111286512A (zh) * 2019-06-05 2020-06-16 南京艾德免疫治疗研究院有限公司 靶向人源化酪氨酸激酶孤儿受体1的嵌合抗原受体及其用途
KR20220035369A (ko) * 2019-06-07 2022-03-22 아디맵 엘엘씨 고 친화도 항-cd3 항체, 및 이의 생성 및 사용 방법
TWI774137B (zh) * 2019-11-26 2022-08-11 大陸商上海岸邁生物科技有限公司 針對cd3和bcma的抗體和自其製備的雙特異性結合蛋白

Similar Documents

Publication Publication Date Title
AU2020359928B2 (en) CD3-targeting antibody, bispecific antibody and use thereof
CN112955471B (zh) Cd3抗体及其药物用途
JP2024510098A (ja) 抗GPRC5DxBCMAxCD3三重特異性抗体およびその使用
JP6702893B2 (ja) 多重特異的抗原結合タンパク質
CN112969476B (zh) 多特异性蛋白分子
JP2021512630A5 (cg-RX-API-DMAC7.html)
JP2022551836A (ja) Bcmaを標的とする抗体、二重特異性抗体及びその用途
CN106831996B (zh) 具有cd3e和/或her2靶向功能的双特异性抗体及其用途
JP2018502050A5 (cg-RX-API-DMAC7.html)
JP2021520832A5 (cg-RX-API-DMAC7.html)
JP7728595B2 (ja) 二重特異性抗体及びその用途
CN111093702A (zh) 靶细胞依赖性T细胞的接合和活化型不对称异二聚Fc-ScFv融合抗体形式用于癌症治疗
CN118946592A (zh) 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途
JP2024543822A5 (cg-RX-API-DMAC7.html)
CN116135884A (zh) 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
WO2023036215A1 (zh) 双特异性抗原结合分子及其应用
JP2026508244A (ja) 抗Nectin-4抗体及びそれを含む多重特異性抗体
JP2025525885A (ja) Gucy2cとcd3に特異的に結合する抗原結合分子及びその医薬的使用
WO2024094151A1 (en) Multi-specific antibody and medical use thereof
KR20260035361A (ko) 폴리오바이러스 수용체에 대한 항체 및 이의 용도
CA3281557A1 (en) Trispecific antigen-binding molecule and use thereof
CA3281554A1 (en) Trispecific antigen-binding molecule and use thereof
HK40101629A (en) Bispecific antibody containing anti-cldn18.2 antibody, and pharmaceutical composition and use thereof
WO2024223710A1 (en) Novel egfr binding proteins
KR20250158060A (ko) 항-cldn6 및 항-cd3 다중특이적 항체 및 사용 방법